Adverse Events in RESIST Trials

Incidence of adverse events
Adverse events leading to discontinuation that occurred in 5.4% of the APTIVUS/r-treated patients and 1.6% of the CPI/r-treated patients.

The most frequent adverse events were diarrhea, nausea, pyrexia, vomiting, fatigue, headache, and abdominal pain. Refer to ritonavir Prescribing Information for ritonavir-associated adverse events.

Percentage of Adult Patients with Treatment-Emergent Adverse Events of at Least Moderate Intensity (Grade 2-4) in ≥2% of Patients Randomized: RESIST Trials (48-Week Analysis)